Payment overview · 2025
General Payments
$1,653.06
110 reported records · 24 companies
Healthcare provider profile · identity verified
James Thomas Kirby, MD
Allopathic & Osteopathic Physicians|Internal Medicine · KNOXVILLE, TN · NPI 1497791438
Verified facts
What the public records show
CMS Open Payments records show James Thomas Kirby, MD received $1,653.06 in general payments during 2025 across 110 reported records.
Novo Nordisk Inc accounted for 12.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 33 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Gemtesa, Jardiance, Linzess, Mounjaro, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Myrbetriq by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 221 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 221 claims for Eliquis by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $210.16 | 12.7% | 18 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $184.95 | 11.2% | 19 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $177.31 | 10.7% | 13 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $152.88 | 9.2% | 10 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $145.99 | 8.8% | 11 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $109.52 | 6.6% | 1 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $82.69 | 5.0% | 4 | 2025 |
| HEARTFLOW, INC. | Unresolved — no canonical attribution shown | $79.34 | 4.8% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $75.80 | 4.6% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $64.58 | 3.9% | 4 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $61.77 | 3.7% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $47.97 | 2.9% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $38.53 | 2.3% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $37.83 | 2.3% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $33.54 | 2.0% | 2 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $22.18 | 1.3% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $21.82 | 1.3% | 1 | 2025 |
| ARS Pharmaceuticals Operations, Inc. | Unresolved — no canonical attribution shown | $20.24 | 1.2% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.23 | 0.9% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$14.57 | 0.9% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $14.38 | 0.9% | 1 | 2025 |
| Echosens North America, Inc. | Unresolved — no canonical attribution shown | $14.11 | 0.8% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.85 | 0.8% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $13.82 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,653.06 | 110 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $177.31 | 13 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $152.88 | 10 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $133.09 | 10 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $118.99 | 12 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $111.77 | 9 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $108.78 | 8 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $99.83 | 9 | 2025 |
Source payment records
|
|||||
| FFRct Normalized: ffrct |
Device | HEARTFLOW, INC. | $79.34 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $77.48 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $72.99 | 7 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $61.77 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $61.02 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $50.79 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $48.45 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $47.97 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $46.83 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $39.84 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $38.53 | 2 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $37.83 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $33.54 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $33.17 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $28.13 | 2 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $22.18 | 1 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $21.82 | 1 | 2025 |
Source payment records
|
|||||
| NEFFY Normalized: neffy |
Drug | ARS Pharmaceuticals Operations, Inc. | $20.24 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $17.75 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $15.17 | 4 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $14.57 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $14.38 | 1 | 2025 |
Source payment records
|
|||||
| Fibroscan Normalized: fibroscan |
Device | Echosens North America, Inc. | $14.11 | 1 | 2025 |
Source payment records
|
|||||
| HORIZANT Normalized: horizant |
Drug | Azurity Pharmaceuticals, Inc. | $13.85 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $13.82 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $3.26 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 221 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 92 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 55 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
78 | 18 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
92 | 20 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
221 | 46 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
92 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
62 | 11 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
55 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
221 | 46 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 649 | 167 |
| Amlodipine Besylate | Amlodipine Besylate | 559 | 148 |
| Atorvastatin Calcium | Atorvastatin Calcium | 520 | 139 |
| Omeprazole | Omeprazole | 355 | 91 |
| Metoprolol Succinate | Metoprolol Succinate | 303 | 80 |
| Losartan Potassium | Losartan Potassium | 285 | 83 |
| Lisinopril | Lisinopril | 283 | 74 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 280 | 79 |
| Pantoprazole Sodium | Pantoprazole Sodium | 266 | 70 |
| Simvastatin | Simvastatin | 250 | 67 |
| Metformin Hcl Er | Metformin Hcl | 236 | 58 |
| Eliquis | Apixaban | 221 | 46 |
| Meloxicam | Meloxicam | 215 | 67 |
| Escitalopram Oxalate | Escitalopram Oxalate | 212 | 59 |
| Gabapentin | Gabapentin | 202 | 45 |
| Hydrochlorothiazide | Hydrochlorothiazide | 188 | 47 |
| Zolpidem Tartrate | Zolpidem Tartrate | 187 | 38 |
| Montelukast Sodium | Montelukast Sodium | 178 | 38 |
| Potassium Chloride | Potassium Chloride | 164 | 44 |
| Sertraline Hcl | Sertraline Hcl | 164 | 44 |
| Tamsulosin Hcl | Tamsulosin Hcl | 135 | 40 |
| Duloxetine Hcl | Duloxetine Hcl | 129 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 122 | 37 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 117 | 33 |
| Famotidine | Famotidine | 112 | 35 |
| Allopurinol | Allopurinol | 107 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 101 | 25 |
| Estradiol | Estradiol | 98 | 27 |
| Citalopram Hbr | Citalopram Hydrobromide | 96 | 27 |
| Jardiance | Empagliflozin | 92 | 20 |
| Glimepiride | Glimepiride | 91 | 25 |
| Trazodone Hcl | Trazodone Hcl | 91 | 25 |
| Celecoxib | Celecoxib | 89 | 28 |
| Furosemide | Furosemide | 86 | 34 |
| Donepezil Hcl | Donepezil Hcl | 84 | 23 |
| Irbesartan | Irbesartan | 83 | 20 |
| Metformin Hcl | Metformin Hcl | 81 | 26 |
| Ezetimibe | Ezetimibe | 80 | 21 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 78 | 60 |
| Synthroid | Levothyroxine Sodium | 78 | 18 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 77 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 72 | 30 |
| Bupropion Xl | Bupropion Hcl | 71 | 23 |
| Carvedilol | Carvedilol | 71 | 18 |
| Alprazolam | Alprazolam | 70 | 21 |
| Atenolol | Atenolol | 68 | 18 |
| Tramadol Hcl | Tramadol Hcl | 65 | 26 |
| Memantine Hcl | Memantine Hcl | 64 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 62 | 20 |
| Trulicity | Dulaglutide | 62 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 61 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 59 | 13 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 58 | 22 |
| Warfarin Sodium | Warfarin Sodium | 58 | suppressed |
| Xarelto | Rivaroxaban | 58 | 12 |
| Pregabalin | Pregabalin | 57 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 56 | 18 |
| Ozempic | Semaglutide | 55 | 13 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 54 | 26 |
| Lovastatin | Lovastatin | 51 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 50 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 48 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 48 | 12 |
| Benazepril Hcl | Benazepril Hcl | 45 | 12 |
| Doxazosin Mesylate | Doxazosin Mesylate | 45 | 14 |
| Lorazepam | Lorazepam | 45 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 44 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 43 | 12 |
| Fluconazole | Fluconazole | 43 | 20 |
| Ramipril | Ramipril | 43 | suppressed |
| Finasteride | Finasteride | 42 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 41 | 14 |
| Valacyclovir | Valacyclovir Hcl | 41 | 16 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 40 | 32 |
| Mounjaro | Tirzepatide | 39 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 38 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 36 | 15 |
| Nebivolol Hcl | Nebivolol Hcl | 36 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 35 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 35 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 34 | suppressed |
| Mirtazapine | Mirtazapine | 34 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 34 | suppressed |
| Fenofibrate | Fenofibrate | 32 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 31 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 30 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 29 | 13 |
| Alendronate Sodium | Alendronate Sodium | 28 | suppressed |
| Nifedipine Er | Nifedipine | 28 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 28 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 28 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | 11 |
| Myrbetriq | Mirabegron | 27 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 27 | 21 |
| Valsartan | Valsartan | 27 | suppressed |
| Chlorthalidone | Chlorthalidone | 26 | suppressed |
| Glipizide | Glipizide | 26 | suppressed |
| Lansoprazole | Lansoprazole | 26 | suppressed |
| Telmisartan | Telmisartan | 25 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 25 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 24 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 24 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 22 | suppressed |
| Linzess | Linaclotide | 22 | suppressed |
| Methocarbamol | Methocarbamol | 22 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | 21 |
| Bumetanide | Bumetanide | 21 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Hydrocortisone | Hydrocortisone | 21 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 21 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 20 | 17 |
| Enalapril Maleate | Enalapril Maleate | 20 | suppressed |
| Ondansetron Odt | Ondansetron | 20 | suppressed |
| Spironolactone | Spironolactone | 20 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 19 | suppressed |
| Baclofen | Baclofen | 19 | suppressed |
| Clonazepam | Clonazepam | 19 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 19 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 19 | suppressed |
| Amoxicillin | Amoxicillin | 18 | 14 |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 17 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 17 | suppressed |
| Primidone | Primidone | 17 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | 14 |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Eszopiclone | Eszopiclone | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | 13 |
| Acyclovir | Acyclovir | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | suppressed |
| Methylprednisolone | Methylprednisolone | 15 | 15 |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Diazepam | Diazepam | 14 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 14 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Benicar | Olmesartan Medoxomil | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Gemtesa | Vibegron | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 11 | suppressed |
| Effexor Xr | Venlafaxine Hcl | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,653.06 · 110 records | Novo Nordisk Inc | AIRSUPRA, CAMZYOS, CREON, Cologuard Collection Kit, ELIQUIS, FFRct, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FREESTYLE LIBRE 3, Fibroscan, GEMTESA, HORIZANT, JARDIANCE, KRYSTEXXA, LEQVIO, LINZESS, MINIMED 780G, MOUNJARO, NEFFY, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, UBRELVY, VOQUEZNA, VRAYLAR, VYEPTI, Veozah, Wegovy, ZAVZPRET, ZEPBOUND | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error